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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Exposure to bosentan was lower in paediatric
pulmonary arterial hypertension (PAH) patients
treated with the marketed adult formulation at a
dose of about 2 mg kg
-1 when compared with adult
PAH patients.
￿ In healthy adult subjects,bosentan
pharmacokinetics are less than dose-proportional at
doses of 500 mg.
WHAT THIS STUDY ADDS
￿ The pharmacokinetics of a new paediatric bosentan
formulation were characterized in paediatric PAH
patients.
￿ The level of exposure to bosentan as observed in
adult PAH patients cannot be reached in paediatric
patients with b.i.d.dosing.
￿ In paediatric PAH patients,nondose-proportional
pharmacokinetics of bosentan occur at lower doses
when compared with healthy adult subjects.
AIM
To show equivalent bosentan exposure in paediatric patients with pulmonary
arterial hypertension (PAH) when compared with a cohort of historical controls
of adult PAH patients using a newly developed paediatric formulation.
METHODS
Thirty-six paediatric PAH patients were enrolled in this multicentre,prospective,
open-label,noncontrolled study and treated for 4 weeks with bosentan
2m gk g
-1 b.i.d.and then for 8 weeks with 4 mg kg
-1 b.i.d.Blood samples were
taken for pharmacokinetic purposes.Exploratory efﬁcacy measurements
included World Health Organization (WHO) functional class and parent’s and
clinician’s Global Clinical Impression scales.
RESULTS
Comparing children with a historical group of adults,the geometric mean ratio
(90% conﬁdence interval) of the area under the plasma concentration–time
curve was 0.54 (0.37,0.78),i.e.children had lower exposure to bosentan than
adults.Bosentan concentrations following doses of 2 and 4 mg kg
-1 were similar.
Improvements in WHO functional class and the Global Clinical Impression scales
occurred mainly in bosentan-naive patients,whereas the rare worsenings
occurred in patients already on bosentan prior to study initiation.The paediatric
formulation was well accepted and bosentan well tolerated in this study.No
cases of elevated liver enzymes or anaemia were reported.
CONCLUSIONS
Exposure to bosentan,as shown comparing the results from this study with
those from a study in adults,was different in paediatric and adult PAH patients.
Since FUTURE-1 and past studies suggest a favourable beneﬁt–risk proﬁle for
bosentan at 2 mg kg
-1 b.i.d.,this dose is recommended for children with PAH.
The new paediatric formulation was well tolerated.
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Pulmonary arterial hypertension (PAH) is a disease of
the pulmonary arterioles characterized by progressive
increases in pulmonary artery pressure and pulmonary
vascular resistance,ultimately resulting in right ventricular
failure and death [1,2].The deﬁnition of PAH in adults and
children is the same: a mean pulmonary artery pressure
>25 mmHg at rest or >30 mmHg during exercise with a
normal pulmonary capillary wedge pressure, and an
increased pulmonary vascular resistance index >3 Wood
units m
2 [1].While histopathology and pathophysiology of
PAH are similar in adults and children [3, 4], the disease is
often more aggressive and more rapidly progressive in
paediatric patients than in adult patients, i.e. the median
survival was 2.8 years in adults but only 10 months in chil-
drenintheNationalInstitutesofHealthPatientRegistryfor
the Characterization of Primary Pulmonary Hypertension
[5].Inchildren,approximately40%ofcasesofPAHareidio-
pathic [6] and approximately 6% are heritable [7],with the
remaindermainlyassociatedwithcongenitalheartdisease
andfewassociatedwithconnectivetissuediseases,human
immunodeﬁciency virus or portal hypertension.A number
of drugs have been approved for the treatment of PAH in
adults, including endothelin receptor antagonists, prosta-
cyclin analogues,and phosphodiesterase type 5 inhibitors
[8].Althoughthesedrugsareusedinpaediatricpatients[9,
10], none has been approved for the treatment of PAH in
children.
Bosentan is an oral dual endothelin receptor antago-
nist with an approved dosing regimen for PAH in adults
weighing >40 kg of 62.5 mg b.i.d.initially followed by upti-
tration to 125 mg b.i.d.after 4 weeks.After oral administra-
tion, maximum plasma concentrations of bosentan were
attained within 3–5 h and the terminal elimination half-life
(t1/2) was about 5 h in healthy adult subjects, with a
maximum plasma concentration (Cmax) of approximately
1000 ng ml
-1. The metabolism of bosentan is dependent
on the activity of CYP2C9 and 3A4 isoenzymes,and excre-
tion of the metabolites via the bile constitutes the major
pathway of elimination. Exposure to bosentan increased
proportionally for doses of 3–600 mg [11].
Current regulatory guidelines consider that when a
drug is to be used in the paediatric population for the
same indication as that for which it is approved in adults,
and if the disease process is not different in paediatric vs.
adult patients, then the treatment effect is likely to be
comparable and extrapolation from adult efﬁcacy data
is appropriate [12]. In such cases, the basis for regulatory
approval is similar pharmacokinetics in children and
adults. In a previous study, paediatric PAH patients were
treated with the marketed (adult) formulation of bosentan
at a dose of approximately 2 mg kg
-1 and the improve-
ment in haemodynamic variables in paediatric patients
was similar to that demonstrated in adult patients [13].
Thereafter, a new formulation was developed providing
more convenient dosing, facilitating administration
and increasing acceptance for paediatric patients, and
pediatric FormUlation of bosenTan in pUlmonary arterial
hypeRtEnsion (FUTURE-1) was designed to evaluate its
pharmacokinetic proﬁle in the target population.Because
it was shown in this previous study that bosentan plasma
concentrations in children were about 50% lower than
those measured in adult PAH patients [11, 13], in the
present study a bosentan dose of 4 mg kg
-1 was selected
in an attempt to achieve similar plasma concentrations
inpaediatricPAHpatientstothoseinadultPAHpatients.In
addition,tolerability,safety and efﬁcacy of the new paedi-
atric bosentan formulation were explored.
Patients and methods
Patients
Enrolled male or female patients (2 and <12 years old)
had idiopathic or heritable PAH in World Health Organiza-
tion (WHO) functional class (FC) II or III as diagnosed by
right heart catheterization, and had a systemic arterial
oxygen saturation at rest of >88%.Patients had to be in a
stable condition regarding their disease and treatment.
Treatments permitted included intravenous (i.v.) epopros-
tenol, inhaled or i.v. iloprost, calcium channel blockers, as
well as bosentan treatment (with the marketed formula-
tion) at the start of this study.Exclusion criteria included a
body weight <4 kg and liver aminotransferases more than
three times the upper limit of normal.
The study was conducted in conformity with the Dec-
larationofHelsinkiandinadherencetolocalguidelinesfor
good clinical practice.The local ethics review committees
approved the protocol. Written informed consent was
obtained from a parent or legal guardian prior to the start
of any study-related procedure. In addition, the patients
were informed about the trial to an extent matching their
capability to understand.
Study design
FUTURE-1 was a prospective,open-label,single-arm study
consisting of a screening period, a 12-week treatment
period,and a 28-day post-treatment follow-up period.The
dose of bosentan was adjusted to the patient’s body
weight at study start. Patients with a body weight <30 kg
received the initial dose of 2 mg kg
-1 b.i.d. for 4 weeks,
which was then uptitrated to the maintenance dose of
4m gk g
-1b.i.d.fortheremainderofthestudy.Patientswith
abodyweight>30 kgreceived64 mgb.i.d.for4weeksand
then120 mgb.i.d.asthemaintenancedose.Thosepatients
who prior to study entry were already on bosentan at a
dose>2m gk g
-1could,atthediscretionoftheinvestigator,
immediately receive the maintenance dose. The new
formulation of bosentan consists of a 32-mg tablet with
quadrisecting score lines.These score lines allow for ﬂex-
ible dosing with 8-mg fractions, which can be dispersed
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contain a ﬂavour and a sweetener. Galenical tests have
shown that the mass of both halved and quartered tablets
iswithintherangeof85–115%ofthetheoreticalmassand
that broken tablets are stable at room temperature for up
to 7 days. After study end and at the discretion of the
treatingphysician,patientshadtheoptiontoparticipatein
an extension phase (FUTURE-2).
Pharmacokinetics
The primary objective of FUTURE-1 was to demonstrate
that at the selected dose the exposure to bosentan
obtained in this study in children with idiopathic or heri-
table PAH was similar to that in adults with PAH (historical
control).
The pharmacokinetic assessment was performed 2
weeks after start of treatment with the maintenance dose,
i.e. at steady state. Patients were hospitalized and an ind-
welling catheter was placed in an arm vein for repeated
blood withdrawal. Blood samples of 1.2 ml were drawn
predose and at 0.5,1,3,7.5 and 12 h post dose in ethylene-
diamine tetraaceticacid-containing tubes. Plasma was
separated and analysed for bosentan and its three
metabolites, Ro 47-8634, Ro 48-5033 and Ro 64-1056, as
described previously [14]. However, in order to minimize
the amount of blood to be withdrawn from the patients,
the volume of plasma to be extracted prior to the chro-
matographic analysis from each sample was divided by 4.
As a consequence,the limits of quantiﬁcation were raised
fourfold to 4 and 8 ng ml
-1 for bosentan and its metabo-
lites, respectively. The day-to-day coefﬁcients of variation
variedbetween6.8and9.0%forbosentananditsmetabo-
lites,and inaccuracy was <5.8%.
Plasma samples were analysed as they became avail-
able.Because the concentrations of bosentan were found
to be lower than expected,it was decided to obtain more
information on dose proportionality of bosentan pharma-
cokinetics.Thus,inasubsetofpatientsthepharmacokinet-
ics of bosentan were assessed both 2 weeks after study
druginitiationand2weeksafteruptitrationtothemain-
tenance dose.
The pharmacokinetic evaluation of bosentan and its
metaboliteswasperformedasdescribedpreviously[13],in
order to obtain values for the Cmax, the time to Cmax (tmax),
and the area under the plasma concentration–time curve
during a dose interval (AUCt) using noncompartmental
analysis.
Tolerability and safety
Tolerability and safety were evaluated by monitoring
adverse events, vital signs, body weight, physical exami-
nation, premature discontinuations, laboratory tests
(including monthly liver function tests), and 12-lead
electrocardiogram.
Exploratory efﬁcacy
WHO FC, a quality-of-life questionnaire (10-item Short
Form survey for children, SF-10 [15]), and Global Clinical
Impression scales [16] were completed by parents and
investigators to assess clinical outcomes. Assessments
were performed at baseline, at uptitration to the mainte-
nancedose,duringthepharmacokineticvisits,andatstudy
end.
Statistical analysis
A sample size of 30 patients was chosen with the aim of
rejecting the null hypothesis that the 90% conﬁdence
interval of the geometric mean ratio of AUCt (primary end-
point) in children and adult PAH patients (predeﬁned his-
torical control [11]) was outside the equivalence limits of
0.66and1.50withatypeIerrorof0.05and80%power.The
equivalence limits were chosen based on the AUCt for
bosentananditsvariabilityasobtainedinapreviousstudy
conductedinpaediatricpatients[13].Thegeometricmean
value[95%conﬁdencelimits(95%CL)]ofAUCtofbosentan
in the historical control group of adult PAH patients was
8149 ng h
-1 ml
-1 (6021,11 030).
The calculation of the geometric mean ratio and 90%
two-sided CL (Student’s t-distribution), comparing chil-
drenandadults,wascarriedoutusingtheper-protocolset.
Patients were included in the per-protocol set when they
were able to provide at least ﬁve of the six blood samples
(including predose and 12-h samples) during the pharma-
cokinetic visit when they were on the maintenance dose
and did not violate the protocol in a way that might have
affected evaluation of the primary end-point.The pharma-
cokinetic parameters of bosentan following administra-
tion of 2 and 4 mg kg
-1 were analysed descriptively, as
were data for safety,tolerability and exploratory efﬁcacy.
The effect of the covariates sex,age,body weight,WHO
FC, concomitant treatment with i.v. epoprostenol, and
treatment with bosentan at baseline on the pharmacoki-
netics of bosentan was graphically explored. For the
exploratory efﬁcacy parameters, subgroup analyses were
based on treatment with bosentan at baseline.
Results
Patient characteristics and disposition
A total of 36 patients were enrolled at 11 centres in seven
countries.The demographic and baseline disease charac-
teristicsofthesepatientsareshowninTable 1.Onepatient
was excluded from the per-protocol pharmacokinetic
analysis set because of a dosing error,i.e.the evening dose
on the day of pharmacokinetic assessments was taken
prior to withdrawal of the 12-h blood sample.One patient
was excluded from the exploratory efﬁcacy set because
thepatientunderwentapalliativeprocedure,i.e.atrialsep-
tostomy,not allowing reliable WHO FC and Quality of Life
M.Beghetti et al.
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analysis sets is shown in Figure 1.
Pharmacokinetics
The pharmacokinetic proﬁle of bosentan was character-
ized by a median tmax of 3 h followed by rapid disposition.
Descriptive statistics of pharmacokinetic parameters of
bosentan and its metabolites Ro 48-5033 and Ro 64-1056
afteradministrationofadoseof4 mg kg
-1aresummarized
in Table 2. No pharmacokinetic analysis could be per-
formed for the metabolite Ro 47-8634 because in most
plasma samples the concentration of this metabolite was
belowthelimitofquantiﬁcation.Theratioofthegeometric
meansforAUCtbetweenpaediatricandadultpatientswas
0.54 (95% CL 0.37, 0.78), indicating (i) that exposure to
bosentan in children in the current study was half the
exposure found in adult patients,and (ii) that the ratio was
not within the predeﬁned equivalence limits of 0.66–1.50.
When comparing bosentan-naive patients at study start
with those already on bosentan, it was noted that the
AUCt of bosentan was similar in both subgroups
(4298 ng h
-1 ml
-1,95% CL 3497,5282;and 4514 ng h
-1 ml
-1,
95% CL 2594,7855,respectively).Exposure to the metabo-
lites Ro 48-5033 and Ro 64-1056 was low compared with
that of bosentan, with Ro 48-5033 having the highest
exposure of these two metabolites. WHO FC and the
dichotomous covariates sex, i.v. epoprostenol treatment,
and bosentan treatment at baseline did not affect the
pharmacokinetics of bosentan (data not shown). In addi-
tion, analysis for the continuous variables age (Figure 2)
and body weight did not show a trend for an effect on
pharmacokinetics.
Figure 3 shows the plasma concentration–time proﬁles
of bosentan following administration of doses of 2 and
4m gk g
-1 in the subgroup of patients who underwent two
pharmacokinetic assessments. The two proﬁles overlap,
yieldingcomparablepharmacokineticparametersforboth
doses (Table 2).
Table 1
Patients’ demographic and baseline disease characteristics
Characteristic* All patients (n = 36)
Gender: male/female, n (%) 21 (58.3)/15 (41.7)
Age, years 7.0 (2.0–11.0)
Age, n (%)
2–3 years 4 (11.1)
4–5 years 9 (25.0)
6–11 years 23 (63.9)
Weight, kg 20.7 (9.5–42.0)
Children below/above 30 kg, n
<30 kg (4 mg kg-1 b.i.d.) 29
30 kg (adult dose, i.e. 125 mg b.i.d.) 7
Height, cm 119.0 (79.0–153.0)
Ethnicity, n (%)
White 32 (88.9)
Black 1 (2.8)
Hispanic 2 (5.6)
Other 1 (2.8)
Aetiology, n (%)
Idiopathic 31 (86.1)
Heritable 5 (13.9)
WHO FC, n (%)
FC II 23 (63.9)
FC III 13 (36.1)
*Values are expressed as the median (range) or % when indicated. WHO, World
Health Organization; FC, functional class.
Patients enrolled 
and treated
N = 36 2 Patients discontinued: 
death and bad taste
Patients 
completed
N = 34**
Patients analyzed for 
per-protocol 
exploratory efficacy
N = 35*
1 Patient excluded: 
dosing error
1 Patient excluded: 
palliative procedure
Patients analyzed for 
per-protocol 
pharmacokinetics
N = 35*
* Different patients were excluded from the 2 analysis sets
** Discontinuations occurred after the patients had completed their week 12 and 
pharmacokinetic assessments
Figure 1
Analysis sets and patient disposition
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Two patients prematurely withdrew from the study after
the patients had completed the pharmacokinetic assess-
ments at the maintenance dose. One child withdrew due
to‘bad’taste of the medication and one died.Overall,four
patients(11.1%)experiencedeightseriousadverseevents,
all requiring hospitalization. A 10-year old girl with heri-
table PAH died. She had a history of anaemia, 1p36 chro-
mosomal deletion, encephalopathy, epilepsy, and patent
ductus arteriosus and small ventricular septal defect,both
having closed spontaneously. The patient died of right
ventricular failure following development of an ear infec-
tion.This death was considered by the investigator to be
unrelated to study treatment. There were six additional
serious adverse events reported in three patients: pre-
planned adenoidectomy and bacterial infection in one
patient;cough,fatigue,and an episode of systemic hyper-
tensioninanother;andworseningofpulmonaryhyperten-
sion in the third. Only the latter event was judged as
related to study treatment by the investigator.Twenty-two
patients (61%) experienced at least one adverse event.The
most frequent (frequency >5%) individual adverse events
were:abdominal pain (four events,11.1%);vomiting (three
events,8.3%);upper abdominal pain,aggression,asthenia,
bronchitis, chest pain, fatigue, ﬂushing, headache, nasal
congestion, pain in extremity, pulmonary hypertension,
tonsillitis, viral infection (two events each, 5.6%). When
Table 2
Pharmacokinetic parameters* of bosentan and its metabolites in paediatric pulmonary arterial hypertension patients after multiple-dose administration of
bosentan at a dose of 2 and/or 4 mg kg-1 b.i.d.
Patient population/
analyte/dose Cmax (ng ml-1) tmax (h) AUCt (ng h-1 ml-1)
All patients (n = 35)
Bosentan (4 mg kg-1) 895 (699, 1146) 3.0 (0.0–8.5) 4383 (3461, 5552)
Ro 48-5033 91 (67, 123) 3.0 (0.0–12.0) 555 (431, 715)
Ro 64-1056 72 (56, 91) 3.0 (0.0–12.0) 501 (391, 643)
Patients with two pharmacokinetic assessments (n = 11)
Bosentan
2m gk g -1 583 (354, 961) 3.0 (1.0–7.5) 3577 (2294, 5577)
4m gk g -1 649 (444, 949) 3.0 (0.0–7.5) 3371 (2344, 4849)
Ro 48-5033
2m gk g -1 71 (45, 112) 0.5 (0.0–7.5) 486 (305, 774)
4m gk g -1 57 (33, 97) 3.0 (0.0–7.5) 423 (247, 726)
Ro 64-1056
2m gk g -1 76 (45, 130) 3.0 (0.0–12.0) 512 (295, 889)
4m gk g -1 61 (43, 85) 3.0 (0.0–7.5) 444 (279, 707)
*Data are expressed as geometric means (95% conﬁdence limits) for Cmax and AUCt, and as median (range) for tmax.
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Individual AUCt values of bosentan in paediatric (dose = 4m gk g -1 b.i.d.;
n = 35) and adult pulmonary arterial hypertension (dose ª 1 . 8m gk g
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Figure 3
Arithmetic mean (SD) plasma concentration vs. time proﬁles of bosen-
tan in paediatric pulmonary arterial hypertension patients after multiple-
dose administration of bosentan at a dose of 2 and 4 mg kg
-1 b.i.d.
(n = 11).2 mg kg-1 ( ) ;4m gk g -1 ( )
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were infections (mainly respiratory) and gastrointestinal
disorders, which were reported in 12 and nine patients,
respectively.All patients except one completed treatment
withbosentanandthemajorityofadverseeventsresolved
while bosentan was ongoing.The patient who discontin-
ued bosentan initially developed an ear infection, which
triggered right heart failure requiring hospitalization.The
studydrugwasdiscontinued.Theeventresultedindeath1
day later. There were no cases of elevated liver enzymes,
anaemia or any other clinically relevant abnormality. No
changes in vital signs, body weight or ECG parameters
were reported.
Exploratory efﬁcacy
The changes from baseline to weeks 4, 8 and 12 in WHO
FC showed that the majority of patients remained
unchanged. At study end, of the 23 patients at baseline
who were in FC II, only one worsened to FC III and two
improved to FC I.The remaining 20 patients were stable at
FC II. Of the 12 patients who were FC III at baseline, none
worsened, and three improved to FC II. Results from the
parents’ and investigator’s Global Clinical Impression
scales at study end compared with baseline were available
for 34 and 35 patients,respectively.In most cases,parents’
responses were consistent with, or more favourable than,
the physicians’ assessments. Of the 17 patients whose
condition the parents rated ‘not good or bad’ or ‘bad’ at
baseline,nine were considered to be doing‘better’or‘sig-
niﬁcantly better’ at week 12. Of the 17 patients whose
condition the parents rated ‘good’ or ‘very good’ at base-
line,only one was considered to be doing‘worse’or‘signi-
ﬁcantly worse’ at week 12, with nine patients considered
being either ‘signiﬁcantly better’ or ‘better’ at week 12. Of
11 patients whose condition the physician rated ‘not
good or bad’ or ‘bad’ at baseline, six were considered to
be doing‘better’or‘signiﬁcantly better’by week 12.Of 24
patients whose condition the physician rated ‘good’ or
‘very good’ at baseline, only two were considered to be
doing ‘worse’ or ‘signiﬁcantly worse’, with the majority
of responses being ‘no change’ or ‘better’, at week 12.
The SF-10 Physical Summary and Psychological Summary
scores showed a clinically nonsigniﬁcant improvement
(data not shown).
When comparing bosentan-naive patients at baseline
with those previously treated with this drug, all patients
who showed signs of worsening during the study were in
the latter group. Furthermore, signs of clinical improve-
ment were greater in bosentan-naive patients,irrespective
of the instrument used to assess efﬁcacy.
Discussion
In this study,the pharmacokinetics and clinical proﬁle of a
new paediatric formulation of bosentan were investigated
in children with idiopathic or heritable PAH. The primary
objective of demonstrating equivalent exposure to bosen-
tan in paediatric and adult PAH patients was not met.
Bosentan plasma concentrations in children were lower
than those in adults despite doubling the dose from 2 to
4m gk g
-1.Data from the subgroup of patients who under-
went two pharmacokinetic assessments showed that the
plasma concentration–time proﬁles of bosentan following
administration of doses of 2 and 4 mg kg
-1 overlapped,
suggesting that an exposure plateau was reached at a
dose of 2 mg kg
-1.In healthy adults,the pharmacokinetics
of bosentan are dose-proportional up to a dose of 500 mg
(approximately7 mg kg
-1forabodyweightof70 kg)given
once a day,but the AUCt at a dose of 1000 mg was similar
to that of 500 mg [17].The FUTURE-1 ﬁndings in children
are in accordance with the nondose-proportional pharma-
cokinetics of bosentan in adults,although the dose above
whichnofurtherincreaseinexposureoccursappearstobe
lower in children.
To explain the observed exposure plateau in adults,
it was suggested that the low solubility of bosentan
may result in saturable absorption at higher doses [17].
However, this does not explain why in children the expo-
sure plateau occurs at lower doses.A possible explanation
in children could be the smaller size of their intestinal
surface area and/or different absorption characteristics,
resulting in a lower capacity for absorption.Given that the
apparent elimination half-life of bosentan was similar in
paediatric [13] and adult patients (Actelion Pharmaceuti-
cals,data on ﬁle),it is unlikely that the observed exposure
plateau is due to a difference in metabolic or excretory
capacity between these patient populations. It is also
unlikely that a difference in formulation is the reason for
this,because it has been shown that the marketed formu-
lation was bioequivalent to an oral suspension in healthy
adults [18].This oral suspension has similar physicochemi-
cal properties to the paediatric formulation when sus-
pended in water.
Except for the difference in dose at which bosentan
pharmacokinetics deviate from being proportional, the
pharmacokinetic characteristics of bosentan in children
and adults, in terms of time to maximum concentration
and elimination, are comparable [11, 13]. Furthermore,
there is a substantial overlap in exposure to bosentan, as
shown in Figure 2.The plasma concentrations measured in
this study are in the same range as those observed in a
previous study with paediatric patients in which the mar-
keted bosentan formulation at a dose of approximately
2m gk g
-1 was administered [13], further indicating that
the marketed and the new paediatric formulations have
similar pharmacokinetic proﬁles. In this previous study,
treatment with bosentan resulted in an increase in cardiac
index of 0.5 l min
-1 m
-2, a decrease in mean pulmonary
artery pressure of 8 mmHg and a decrease in pulmonary
vascular resistance index of 3.8 Wood units m
2 after
12 weeks. These haemodynamic improvements were of
Pharmacokinetics of a new paediatric bosentan formulation
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despite the lower bosentan plasma concentrations in
children suggesting that efﬁcacy is achieved with a dose
o f2m gk g
-1. This dose is used in clinical practice, and a
number of clinicians have published their experience with
bosentan in children. Rosenzweig et al. [9] reported on a
cohort of 86 paediatric PAH patients, treated with bosen-
tan monotherapy or added to treatment with prostacyclin
analogue treatment, and of these patients 90% improved
or remained unchanged in WHO FC after a median treat-
ment duration of 14 months.The patients in the report by
Rosenzweiget al.werealsoallowedtohaveadditionalPAH
medications at the discretion of the clinical investigator.
Comparable results were reported by Maiya et al. [20].
It thus appears that a dose of 2 mg kg
-1 is an effective
and safe dose for children.Based on the pharmacokinetic
results of the current study,higher doses are unlikely to be
more effective. Thus, based on an overall risk–beneﬁt
proﬁle (including signiﬁcant long-term observational
data), we recommend treating children with PAH with
bosentan at the 2 mg kg
-1 dose b.i.d.regimen.
The covariates age and body weight had no effect on
the pharmacokinetics of bosentan, indicating that dosing
children on a mg kg
-1 basis up to 30 kg is appropriate.
Concomitant treatment with i.v. epoprostenol did not
affect bosentan pharmacokinetics, consistent with what
has been shown previously [13].
Treatment with the new formulation of bosentan was
well tolerated by the children; one child discontinued
treatment because of a bad taste. When compared with
adult patients, no new safety ﬁndings were observed. Of
note, no cases of elevated liver aminotransferases were
observed. This could be due to the short duration of the
trial, i.e. 12 weeks, plasma concentrations of bosentan
beinglowerthaninadults,and/orlackofrightheartfailure
in the children as opposed to many adult patients. In
placebo-controlled trials in adult PAH patients, elevations
of liver aminotransferases (more than three times the
upperlimitofnormal)occurredin12.8%ofthepopulation
(n = 258;median exposure time to bosentan 18.8 months)
[21], and they appeared to be dose dependent [22]. In a
paediatric cohort,such elevations occurred in only 3.5% of
the patients (n = 86;median exposure time 14 months) [9].
A recent review of the safety data of bosentan,as captured
in an internet-based post-marketing database of 4589
bosentan-naive PAH patients, showed a similar low inci-
dence of elevated liver aminotransferases in children aged
2–11 years (2.7%; n = 146) compared with patients aged
12 years (7.8%; n = 4443) [6]. Together, these results
appear to indicate that bosentan is better tolerated in chil-
dren than in adults.
The exploratory efﬁcacy and quality-of-life analyses
indicated that most patients remained unchanged from
baseline to end of study. Observations in bosentan-naive
patients vs. patients previously treated with bosentan
suggest a beneﬁcial therapeutic effect following initiation
ofbosentan.Thefewpatientswhoshoweddeteriorationin
these outcomes were all on bosentan at the time of study
initiation, indicating progression of this severe disease
although patients were on PAH-speciﬁc therapy. These
exploratory efﬁcacy results should be interpreted with
caution due to the open-label nature of the study,the lack
of a control group, and the relatively small number of
patients. No double-blind, randomized trials have been
performed with bosentan in children. Such trials are not
feasible given the low patient numbers, and the severity
and not infrequently rapidly progressive nature of idio-
pathic and heritable PAH in children compared with adult
patients.
Inconclusion,exposuretobosentan,asshowncompar-
ing the results from this study with those from a study in
adults, was different in paediatric and adult PAH patients.
An exposure plateau appears to be reached in children at
the dose of 2 mg kg
-1 b.i.d.Nevertheless, the pharmacoki-
netic proﬁles were similar between the marketed adult
formulation and the new paediatric formulation. Since
FUTURE-1,in accordance with previous studies,suggests a
favourable beneﬁt–risk proﬁle for bosentan at 2 mg kg
-1
b.i.d.,this dose is recommended for children with PAH.The
new paediatric formulation was well tolerated and may be
better accepted by children due to its more convenient
dosing and the sweet taste.
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